Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
CA 2540730 C · Owner: Schuppan, Detlef · Inventors: Patsenker, Eleonora; Jonczyk, Alfred; Wiesner, Matthias
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to inhibition of .alpha.v integrins especially , .alpha.v.szlig.3 and .alpha.v.szlig.6 integrins by specific antagonists, preferably non-peptidic antagonists related compounds and compounds with , comparable specificity that downregulate fibrogenesis by inhibiting cell migration and production of pro-fibrogenic molecules (e.g. collagens TIMP-1) , and cytokines (e.g. CTGF) by activated hepatic stellate cells/myofibroblasts activated epithelia and endothelia. These antagonists alone or in combination with other agents can effectively prevent mitigate or even reverse , development of advanced fibrosis such as fibrosis/cirrhosis of the liver and fibrosis of other …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 16, 2004 and granted August 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 16, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 16, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.